Molecular Testing for Coagulation Abnormalities

  • Veshana Ramiah
  • Thomas L. Ortel
Reference work entry


Molecular testing is frequently used in conjunction with other laboratory analyses in the evaluation of patients with hemorrhagic as well as thrombotic disorders. The most common thrombophilic defects, factor V Leiden and the prothrombin G20210A mutation, are detected by molecular testing. Functional assays are used for the less common inherited hypercoagulable states, such as antithrombin or protein C deficiency, since no single mutation has been found to predominate in these deficiency states. Functional assays are also used to identify patients with hemophilia, but genetic analysis of these individuals is frequently performed to aid in the diagnosis of carriers and identify potentially affected children. Patients with thrombotic events are treated with anticoagulant therapy, which has traditionally been warfarin, a vitamin K antagonist. Recently, polymorphisms in CYP 2C9 and VKOR1 have been shown to affect the dose of warfarin required to achieve a target international normalized ratio (INR). Similarly, polymorphisms associated with the metabolism of clopidogrel have also been identified. Prospective clinical trials will be necessary to determine the optimal use of this information.


International Normalize Ratio Factor VIII Factor Versus CYP2C19 Genotype Factor Versus Leiden Mutation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Further Reading

  1. Bagnall RD, Waseem N, Green PM, et al. Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. Blood. 2002;99:168–74.PubMedCrossRefGoogle Scholar
  2. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64.PubMedCrossRefGoogle Scholar
  3. Bowen DJ, Keeney S. Unleashing the long-distance PCR for detection of the intron 22 inversion of the factor VIII gene in severe haemophilia A. Thromb Haemost. 2003;89:201–2.PubMedGoogle Scholar
  4. Brinke A, Tagliavacca L, Naylor J, et al. Two chimaeric transcription units result from an inversion breaking intron 1 of the factor VIII gene and a region reportedly affected by reciprocal translocations in T-cell leukaemia. Hum Mol Genet. 1996;5:1945–51.PubMedCrossRefGoogle Scholar
  5. Cattaneo M. The clinical relevance of response variability to antiplatelet therapy. Hematology Am Soc Hematol Educ Program. 2011;2011:70–5.PubMedCrossRefGoogle Scholar
  6. Dahlback B. Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene. Haemostasis. 1994;24:139.PubMedGoogle Scholar
  7. Doggen CJM, Kunz G, Rosendaal FR, et al. A mutation in the thrombomodulin gene, 127 G to A coding for A1a25Thr, and the risk of myocardial infarction. Thromb Haemost. 1998;80:743.PubMedGoogle Scholar
  8. Gardemann A, Schwartz O, Haberbosch W, et al. Positive association of the b fibrinogen H1/H2 gene variation to basal fibrinogen levels and to increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction. Thromb Haemost. 1997;77:1120.PubMedGoogle Scholar
  9. Gong IY, Schwarz UI, Crown N, et al. Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. PLoS One. 2011;6:e27808.PubMedCrossRefGoogle Scholar
  10. Hooper WC, Lally C, Austin H, et al. The role of the tissue-type plasminogen activator I/D and PAI-1 4 G/5G polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism. Thromb Res. 2000;1:223–30.CrossRefGoogle Scholar
  11. Kangelaris KN, Bent S, Nussbaum RL, et al. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med. 2009;24:656–64.PubMedCrossRefGoogle Scholar
  12. Key N, McGlennen RC. Hyperhomocysteinemia. Arch Pathol Lab Med. 2002;126:1367–75.PubMedGoogle Scholar
  13. Kohler HP, Futers T, Grant P. Prevalence of three common polymorphisms in the a-subunit gene of factor XIII in patients with coronary artery disease: association with FXIII activity and antigen levels. Thromb Haemost. 1999;81:511.PubMedGoogle Scholar
  14. Koster T, Blann AD, Briet E, et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis. Lancet. 1995;345:152.PubMedCrossRefGoogle Scholar
  15. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood. 1999;95:1517–32.Google Scholar
  16. Lindh JD, Holm L, Andersson ML, et al. Influence of CYP2C9 genotype on warfarin dose requirements – a systematic review and meta-analysis. Eur J Clin Pharmacol. 2009;65:365–75.PubMedCrossRefGoogle Scholar
  17. Liu Q, Nozari G, Steve S. Sommer single tube polymerase chain reaction for rapid diagnosis of the inversion hotspot of mutation in hemophilia A. Blood. 1998;92:1458–9.PubMedGoogle Scholar
  18. McGlennen RC, Key N. Clinical and laboratory management of the prothrombin G20210A mutation, archives of pathology and laboratory. Medicine. 2002;126:1319–25.Google Scholar
  19. Mega JL, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. A meta-analysis. JAMA. 2010;304:1821–30.PubMedCrossRefGoogle Scholar
  20. Nguyen V, et al. Robust dosage (RD)-PCR protocol for the detection of heterozygous deletions. Biotechniques. 2004;37:360–4.PubMedGoogle Scholar
  21. Tybjaerg-Hansen A, Agerholm-Larsen B, Humphries SE, et al. A common mutation (G−455-A) in the b-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease: a study of 9,127 individuals based on the Copenhagen City Heart Study. J Clin Invest. 1997;99:3034.PubMedCrossRefGoogle Scholar
  22. Voorberg J, Roelse J, Koopman R, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet. 1994;343:1535.PubMedCrossRefGoogle Scholar
  23. Wang XL, Wang J, McCredie RM, et al. Polymorphisms of factor V, factor VII, and fibrinogen genes: relevance to severity of coronary artery disease. Arterioscler Thromb Vasc Biol. 1997;17:246.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Veshana Ramiah
    • 1
  • Thomas L. Ortel
    • 2
  1. 1.Department of Hematology and OncologyDanville Regional Medical CenterDanvilleUSA
  2. 2.Departments of Medicine/Hematology and PathologyDuke University Medical CenterDurhamUSA

Personalised recommendations